The results of two studies have demonstrated that the use of temozolomide (TMZ) plus radiation increases disease-free and overall survival in patients with glioblastoma and a low grade glioma called anaplastic glioma. Continue reading
The worldwide market for cancer immunotherapies is anticipated to grow from $1.1B in 2012 to $9B in 2022, that equals a 23/8% annual growth. Leading the growth are the immune checkpoint inhibitors.
Immune checkpoint control is the hottest area in cancer immunology. Indeed, the checkpoint inhibitors have shown great activity in a variety of cancers. This article http://online.wsj.com/article/PR-CO-20140506-908279.html) summarizes 2 approaches that Merck is taking… Continue reading